AP
LCTX icon

Anchyra Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Anchyra Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.5K Buy
+15,141
New +$16.7K ﹤0.01% 429

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
HA
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Anchyra Partners's LCTX Position: Q3 2026 in Review

Anchyra Partners opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 15,141 shares worth $14.5K. The stake represents ﹤0.01% of the portfolio and ranks #429 among its holdings.

11 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Anchyra Partners held 15,141 shares of Lineage Cell Therapeutics worth $14.5K as of Q3 2026.
  • Lineage Cell Therapeutics was a new Anchyra Partners position in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Anchyra Partners's portfolio in Q3 2026, its #429 holding.
  • 11 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Anchyra Partners's 13F filing for Q3 2026, filed 13 Oct 2026.